10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

AEON (AEON Biopharma, Inc.) Stock Analysis
Buy, Hold or Sell?

Let's analyze AEON Biopharma, Inc. together

I guess you are interested in AEON Biopharma, Inc.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – AEON Biopharma, Inc.’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – AEON Biopharma, Inc.’s Price Targets

I'm going to help you getting a better view of AEON Biopharma, Inc.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about AEON Biopharma, Inc.

I send you an email if I find something interesting about AEON Biopharma, Inc..

1. Quick Overview

1.1. Quick analysis of AEON Biopharma, Inc. (30 sec.)










1.2. What can you expect buying and holding a share of AEON Biopharma, Inc.? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-2.71
Expected worth in 1 year
$20.25
How sure are you?
42.9%

+ What do you gain per year?

Total Gains per Share
$22.96
Return On Investment
4,784.5%

For what price can you sell your share?

Current Price per Share
$0.48
Expected price per share
$0.375 - $7.2936
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of AEON Biopharma, Inc. (5 min.)




Live pricePrice per Share (EOD)
$0.48

2.2. Growth of AEON Biopharma, Inc. (5 min.)




Is AEON Biopharma, Inc. growing?

Current yearPrevious yearGrowGrow %
How rich?-$28.5m-$270.4m$198.6m276.9%

How much money is AEON Biopharma, Inc. making?

Current yearPrevious yearGrowGrow %
Making money$10.5m-$16.5m$27m257.2%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of AEON Biopharma, Inc. (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of AEON Biopharma, Inc.?

Welcome investor! AEON Biopharma, Inc.'s management wants to use your money to grow the business. In return you get a share of AEON Biopharma, Inc..

First you should know what it really means to hold a share of AEON Biopharma, Inc.. And how you can make/lose money.

Speculation

The Price per Share of AEON Biopharma, Inc. is $0.4799. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of AEON Biopharma, Inc..
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in AEON Biopharma, Inc., you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-2.71. Based on the TTM, the Book Value Change Per Share is $5.74 per quarter. Based on the YOY, the Book Value Change Per Share is $-7.91 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of AEON Biopharma, Inc..

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.2041.2%1.10229.9%-1.11-230.3%0.1328.1%0.1328.1%0.1328.1%
Usd Book Value Change Per Share-1.88-391.8%5.741,196.1%-7.91-1,647.8%-0.39-80.7%-0.39-80.7%-0.39-80.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-1.88-391.8%5.741,196.1%-7.91-1,647.8%-0.39-80.7%-0.39-80.7%-0.39-80.7%
Usd Price Per Share0.54-3.56-8.62-5.93-5.93-5.93-
Price to Earnings Ratio0.68--0.30--2.30--1.11--1.11--1.11-
Price-to-Total Gains Ratio-0.29-0.51--2.35--0.52--0.52--0.52-
Price to Book Ratio-0.20--0.62--0.55--0.66--0.66--0.66-
Price-to-Total Gains Ratio-0.29-0.51--2.35--0.52--0.52--0.52-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.4799
Number of shares2083
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share5.74-0.39
Usd Total Gains Per Share5.74-0.39
Gains per Quarter (2083 shares)11,956.96-807.13
Gains per Year (2083 shares)47,827.84-3,228.51
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1047828478180-3229-3239
2095656956460-6457-6468
301434841434740-9686-9697
401913111913020-12914-12926
502391392391300-16143-16155
602869672869580-19371-19384
703347953347860-22600-22613
803826233826140-25828-25842
904304514304420-29057-29071
1004782784782700-32285-32300

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%2.05.00.028.6%2.05.00.028.6%2.05.00.028.6%2.05.00.028.6%
Book Value Change Per Share3.01.00.075.0%3.04.00.042.9%3.04.00.042.9%3.04.00.042.9%3.04.00.042.9%
Dividend per Share0.00.04.00.0%0.00.07.00.0%0.00.07.00.0%0.00.07.00.0%0.00.07.00.0%
Total Gains per Share3.01.00.075.0%3.04.00.042.9%3.04.00.042.9%3.04.00.042.9%3.04.00.042.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of AEON Biopharma, Inc. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.8805.740-133%-7.908+321%-0.387-79%-0.387-79%-0.387-79%
Book Value Per Share---2.712-6.258+131%-18.984+600%-10.408+284%-10.408+284%-10.408+284%
Current Ratio--0.1120.219-49%0.015+646%0.146-23%0.146-23%0.146-23%
Debt To Asset Ratio--10.09322.853-56%26.089-61%24.240-58%24.240-58%24.240-58%
Debt To Equity Ratio----0%-0%-0%-0%-0%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value---26010288.000-29481032.000+13%-132274665.275+409%-54034215.929+108%-54034215.929+108%-54034215.929+108%
Eps--0.1981.103-82%-1.105+659%0.135+47%0.135+47%0.135+47%
Ev To Ebitda Ratio--1.1520.834+38%2.408-52%1.1550%1.1550%1.1550%
Free Cash Flow Per Share---0.059-0.431+630%-0.730+1138%-0.499+746%-0.499+746%-0.499+746%
Free Cash Flow To Equity Per Share---0.050-0.072+45%-0.214+330%-0.167+236%-0.167+236%-0.167+236%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Market Cap5054690.720-13%5687712.00044856218.000-87%148916334.725-96%107562355.500-95%107562355.500-95%107562355.500-95%
Net Profit Margin----0%-0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%-0%
Pb Ratio-0.177+11%-0.199-0.618+211%-0.551+177%-0.656+230%-0.656+230%-0.656+230%
Pe Ratio0.607-13%0.683-0.300+144%-2.297+436%-1.112+263%-1.112+263%-1.112+263%
Price Per Share0.480-13%0.5403.560-85%8.615-94%5.931-91%5.931-91%5.931-91%
Price To Free Cash Flow Ratio-2.035+11%-2.290-2.402+5%-3.448+51%-3.521+54%-3.521+54%-3.521+54%
Price To Total Gains Ratio-0.255+11%-0.2870.513-156%-2.348+718%-0.524+82%-0.524+82%-0.524+82%
Quick Ratio--0.0010.120-99%-+100%0.085-99%0.085-99%0.085-99%
Return On Assets--0.663-2.795+522%-1.532+331%-2.493+476%-2.493+476%-2.493+476%
Return On Equity----0%-0%-0%-0%-0%
Total Gains Per Share---1.8805.740-133%-7.908+321%-0.387-79%-0.387-79%-0.387-79%
Usd Book Value---28569000.000-71746750.000+151%-270413000.000+847%-156889428.571+449%-156889428.571+449%-156889428.571+449%
Usd Book Value Change Per Share---1.8805.740-133%-7.908+321%-0.387-79%-0.387-79%-0.387-79%
Usd Book Value Per Share---2.712-6.258+131%-18.984+600%-10.408+284%-10.408+284%-10.408+284%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value---26010288.000-29481032.000+13%-132274665.275+409%-54034215.929+108%-54034215.929+108%-54034215.929+108%
Usd Eps--0.1981.103-82%-1.105+659%0.135+47%0.135+47%0.135+47%
Usd Free Cash Flow---621000.000-5073000.000+717%-10571500.000+1602%-7128285.714+1048%-7128285.714+1048%-7128285.714+1048%
Usd Free Cash Flow Per Share---0.059-0.431+630%-0.730+1138%-0.499+746%-0.499+746%-0.499+746%
Usd Free Cash Flow To Equity Per Share---0.050-0.072+45%-0.214+330%-0.167+236%-0.167+236%-0.167+236%
Usd Market Cap5054690.720-13%5687712.00044856218.000-87%148916334.725-96%107562355.500-95%107562355.500-95%107562355.500-95%
Usd Price Per Share0.480-13%0.5403.560-85%8.615-94%5.931-91%5.931-91%5.931-91%
Usd Profit--2082000.00010501250.000-80%-16509000.000+893%-3653714.286+275%-3653714.286+275%-3653714.286+275%
Usd Revenue----0%-0%-0%-0%-0%
Usd Total Gains Per Share---1.8805.740-133%-7.908+321%-0.387-79%-0.387-79%-0.387-79%
 EOD+3 -5MRQTTM+14 -16YOY+23 -73Y+17 -135Y+17 -1310Y+17 -13

3.3 Fundamental Score

Let's check the fundamental score of AEON Biopharma, Inc. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-150.607
Price to Book Ratio (EOD)Between0-1-0.177
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.001
Current Ratio (MRQ)Greater than10.112
Debt to Asset Ratio (MRQ)Less than110.093
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.050.663
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of AEON Biopharma, Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.491
Total1/1 (100.0%)

4. In-depth Analysis

4.1 About AEON Biopharma, Inc.

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.

Fundamental data was last updated by Penke on 2025-04-20 02:44:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ AEON Biopharma, Inc. earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ AEON Biopharma, Inc. to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of AEON Biopharma, Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--92.5%+92.5%
TTM--182.1%+182.1%
YOY--197.2%+197.2%
3Y--242.9%+242.9%
5Y--348.0%+348.0%
10Y--488.5%+488.5%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ AEON Biopharma, Inc. is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ AEON Biopharma, Inc. to theΒ Biotechnology industry mean.
  • 66.3% Return on Assets means thatΒ AEON Biopharma, Inc. generatedΒ $0.66 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of AEON Biopharma, Inc.:

  • The MRQ is 66.3%. Using its assets, the company is very efficient in making profit. +2
  • The TTM is -279.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ66.3%TTM-279.5%+345.8%
TTM-279.5%YOY-153.2%-126.4%
TTM-279.5%5Y-249.3%-30.2%
5Y-249.3%10Y-249.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ66.3%-11.3%+77.6%
TTM-279.5%-11.6%-267.9%
YOY-153.2%-11.5%-141.7%
3Y-249.3%-11.7%-237.6%
5Y-249.3%-12.6%-236.7%
10Y-249.3%-14.2%-235.1%
4.3.1.3. Return on Equity

Shows how efficient AEON Biopharma, Inc. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ AEON Biopharma, Inc. to theΒ Biotechnology industry mean.
  • 0.0% Return on Equity means AEON Biopharma, Inc. generated $0.00Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of AEON Biopharma, Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--15.0%+15.0%
TTM--15.1%+15.1%
YOY--15.1%+15.1%
3Y--17.6%+17.6%
5Y--18.1%+18.1%
10Y--20.1%+20.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of AEON Biopharma, Inc..

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient AEON Biopharma, Inc. is operatingΒ .

  • Measures how much profit AEON Biopharma, Inc. makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ AEON Biopharma, Inc. to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of AEON Biopharma, Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--184.5%+184.5%
TTM--287.9%+287.9%
YOY--208.5%+208.5%
3Y--244.6%+244.6%
5Y--355.2%+355.2%
10Y--475.0%+475.0%
4.3.2.2. Operating Ratio

Measures how efficient AEON Biopharma, Inc. is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of AEON Biopharma, Inc.:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.181-2.181
TTM-3.031-3.031
YOY-2.985-2.985
3Y-3.629-3.629
5Y-4.790-4.790
10Y-6.545-6.545
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of AEON Biopharma, Inc..

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if AEON Biopharma, Inc. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 0.11Β means the company has $0.11 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of AEON Biopharma, Inc.:

  • The MRQ is 0.112. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.219. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.112TTM0.219-0.106
TTM0.219YOY0.015+0.204
TTM0.2195Y0.146+0.072
5Y0.14610Y0.1460.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1123.588-3.476
TTM0.2193.932-3.713
YOY0.0154.272-4.257
3Y0.1464.797-4.651
5Y0.1465.817-5.671
10Y0.1466.172-6.026
4.4.3.2. Quick Ratio

Measures if AEON Biopharma, Inc. is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ AEON Biopharma, Inc. to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.00Β means the company can pay off $0.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of AEON Biopharma, Inc.:

  • The MRQ is 0.001. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.120. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.001TTM0.120-0.119
TTM0.120YOY-+0.120
TTM0.1205Y0.085+0.034
5Y0.08510Y0.0850.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0012.845-2.844
TTM0.1203.420-3.300
YOY-4.105-4.105
3Y0.0854.661-4.576
5Y0.0855.882-5.797
10Y0.0856.505-6.420
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of AEON Biopharma, Inc..

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of AEON Biopharma, Inc.Β assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ AEON Biopharma, Inc. to Biotechnology industry mean.
  • A Debt to Asset Ratio of 10.09Β means that AEON Biopharma, Inc. assets areΒ financed with 1,009.3% credit (debt) and the remaining percentage (100% - 1,009.3%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of AEON Biopharma, Inc.:

  • The MRQ is 10.093. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 22.853. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ10.093TTM22.853-12.760
TTM22.853YOY26.089-3.237
TTM22.8535Y24.240-1.387
5Y24.24010Y24.2400.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.0930.342+9.751
TTM22.8530.342+22.511
YOY26.0890.330+25.759
3Y24.2400.329+23.911
5Y24.2400.359+23.881
10Y24.2400.382+23.858
4.5.4.2. Debt to Equity Ratio

Measures ifΒ AEON Biopharma, Inc. is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ AEON Biopharma, Inc. to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of AEON Biopharma, Inc.:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.409-0.409
TTM-0.427-0.427
YOY-0.406-0.406
3Y-0.436-0.436
5Y-0.447-0.447
10Y-0.498-0.498
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings AEON Biopharma, Inc. generates.

  • Above 15 is considered overpriced butΒ always compareΒ AEON Biopharma, Inc. to theΒ Biotechnology industry mean.
  • A PE ratio of 0.68 means the investor is paying $0.68Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of AEON Biopharma, Inc.:

  • The EOD is 0.607. Based on the earnings, the company is cheap. +2
  • The MRQ is 0.683. Based on the earnings, the company is cheap. +2
  • The TTM is -0.300. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.607MRQ0.683-0.076
MRQ0.683TTM-0.300+0.983
TTM-0.300YOY-2.297+1.997
TTM-0.3005Y-1.112+0.812
5Y-1.11210Y-1.1120.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.607-1.851+2.458
MRQ0.683-2.438+3.121
TTM-0.300-3.022+2.722
YOY-2.297-3.297+1.000
3Y-1.112-4.006+2.894
5Y-1.112-6.199+5.087
10Y-1.112-6.796+5.684
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of AEON Biopharma, Inc.:

  • The EOD is -2.035. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.290. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.402. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.035MRQ-2.290+0.255
MRQ-2.290TTM-2.402+0.112
TTM-2.402YOY-3.448+1.046
TTM-2.4025Y-3.521+1.119
5Y-3.52110Y-3.5210.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.035-2.532+0.497
MRQ-2.290-3.298+1.008
TTM-2.402-3.938+1.536
YOY-3.448-4.309+0.861
3Y-3.521-5.461+1.940
5Y-3.521-8.408+4.887
10Y-3.521-9.443+5.922
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ AEON Biopharma, Inc. is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of -0.20 means the investor is paying $-0.20Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of AEON Biopharma, Inc.:

  • The EOD is -0.177. Based on the equity, the company is expensive. -2
  • The MRQ is -0.199. Based on the equity, the company is expensive. -2
  • The TTM is -0.618. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.177MRQ-0.199+0.022
MRQ-0.199TTM-0.618+0.419
TTM-0.618YOY-0.551-0.067
TTM-0.6185Y-0.656+0.038
5Y-0.65610Y-0.6560.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.1771.813-1.990
MRQ-0.1992.184-2.383
TTM-0.6182.403-3.021
YOY-0.5512.480-3.031
3Y-0.6562.766-3.422
5Y-0.6563.735-4.391
10Y-0.6564.330-4.986
4.6.2. Total Gains per Share

2.4. Latest News of AEON Biopharma, Inc.

Does AEON Biopharma, Inc. still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from AEON Biopharma, Inc. to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-04-25
22:05
AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing ComplianceRead
2025-04-21
22:10
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711Read
2025-04-21
22:05
AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive OfficerRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of AEON Biopharma, Inc..

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets3,142
Total Liabilities31,711
Total Stockholder Equity-28,569
 As reported
Total Liabilities 31,711
Total Stockholder Equity+ -28,569
Total Assets = 3,142

Assets

Total Assets3,142
Total Current Assets1,590
Long-term Assets1,552
Total Current Assets
Cash And Cash Equivalents 13
Other Current Assets 1,577
Total Current Assets  (as reported)1,590
Total Current Assets  (calculated)1,590
+/-0
Long-term Assets
Property Plant Equipment 1,523
Long-term Assets Other 29
Long-term Assets  (as reported)1,552
Long-term Assets  (calculated)1,552
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities14,149
Long-term Liabilities17,562
Total Stockholder Equity-28,569
Total Current Liabilities
Short-term Debt 121
Accounts payable 5,910
Other Current Liabilities 7,549
Total Current Liabilities  (as reported)14,149
Total Current Liabilities  (calculated)13,580
+/- 569
Long-term Liabilities
Long term Debt 11,689
Capital Lease Obligations 1,266
Long-term Liabilities Other 3,541
Long-term Liabilities  (as reported)17,562
Long-term Liabilities  (calculated)16,496
+/- 1,066
Total Stockholder Equity
Common Stock4
Retained Earnings -431,597
Other Stockholders Equity 403,024
Total Stockholder Equity (as reported)-28,569
Total Stockholder Equity (calculated)-28,569
+/-0
Other
Capital Stock4
Cash and Short Term Investments 13
Common Stock Shares Outstanding 1,111
Liabilities and Stockholders Equity 3,142
Net Debt 12,942
Net Invested Capital -16,880
Net Working Capital -12,559
Property Plant and Equipment Gross 1,790
Short Long Term Debt Total 12,955



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-09-302023-06-302023-03-312022-12-312022-09-302021-12-312021-06-302020-12-31
> Total Assets 
21,214
18,796
6,436
0
10,778
0
0
17,619
3,032
5,734
4,004
3,142
3,1424,0045,7343,03217,6190010,77806,43618,79621,214
   > Total Current Assets 
20,376
17,455
5,154
0
9,838
0
2,662
16,911
2,498
4,019
2,371
1,590
1,5902,3714,0192,49816,9112,66209,83805,15417,45520,376
       Cash And Cash Equivalents 
20,168
10,605
5,128
0
9,746
0
0
16,177
1,558
3,442
537
13
135373,4421,55816,177009,74605,12810,60520,168
       Net Receivables 
0
5,443
0
0
0
0
0
0
0
0
0
0
00000000005,4430
       Other Current Assets 
208
1,407
26
0
92
0
0
734
940
577
1,834
1,577
1,5771,83457794073400920261,407208
   > Long-term Assets 
838
1,341
1,282
0
940
0
0
708
534
1,715
1,633
1,552
1,5521,6331,7155347080094001,2821,341838
       Property Plant Equipment 
0
0
922
0
906
0
764
679
505
1,686
1,604
1,523
1,5231,6041,6865056797640906092200
       Long-term Assets Other 
838
1,341
360
0
34
0
0
29
29
29
29
29
2929292929003403601,341838
> Total Liabilities 
224,448
226,454
230,260
0
281,191
0
0
139,359
201,413
33,681
36,094
31,711
31,71136,09433,681201,413139,35900281,1910230,260226,454224,448
   > Total Current Liabilities 
4,197
8,839
20,804
0
82,574
0
88,339
14,177
15,957
10,429
10,726
14,149
14,14910,72610,42915,95714,17788,339082,574020,8048,8394,197
       Short-term Debt 
0
0
15,603
0
71,123
0
0
0
205
134
128
121
12112813420500071,123015,60300
       Short Long Term Debt 
0
0
0
0
70,866
0
0
0
0
0
0
0
000000070,8660000
       Accounts payable 
2,031
2,323
1,192
0
7,805
0
6,345
4,013
6,523
3,030
4,630
5,910
5,9104,6303,0306,5234,0136,34507,80501,1922,3232,031
       Other Current Liabilities 
2,166
1,073
4,009
0
3,646
0
0
9,595
8,660
6,696
5,399
7,549
7,5495,3996,6968,6609,595003,64604,0091,0732,166
   > Long-term Liabilities 
220,251
217,615
209,456
0
198,617
0
0
125,182
185,456
23,252
25,368
17,562
17,56225,36823,252185,456125,18200198,6170209,456217,615220,251
> Total Stockholder Equity
-208,273
-215,760
-234,944
0
-287,500
0
0
-121,740
-198,381
-27,947
-32,090
-28,569
-28,569-32,090-27,947-198,381-121,74000-287,5000-234,944-215,760-208,273
   Common Stock
11
14
14
0
14
0
14
4
4
4
4
4
44444140140141411
   Retained Earnings -431,597-433,679-427,508-591,620-423,148-507,8570-474,8390-422,283-403,099-366,646
   Capital Surplus 000000000000
   Treasury Stock000000000000
   Other Stockholders Equity 
158,362
187,325
187,325
0
187,325
0
0
301,404
393,235
399,557
401,585
403,024
403,024401,585399,557393,235301,40400187,3250187,325187,325158,362



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense--72,985
Operating Income72,98572,985
 
Operating Expense (+$)
Research Development14,181
Selling General Administrative13,643
Selling And Marketing Expenses0
Operating Expense-72,98527,824
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income72,985
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)42,005103,965
EBIT - interestExpense = -27,824
42,005
42,005
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-27,82442,005
Earnings Before Interest and Taxes (EBITDA)-27,727
 
After tax Income (+$)
Income Before Tax42,005
Tax Provision-0
Net Income From Continuing Ops42,00542,005
Net Income42,005
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses72,985
Total Other Income/Expenses Net-30,9800
 

Technical Analysis of AEON Biopharma, Inc.
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of AEON Biopharma, Inc.. The general trend of AEON Biopharma, Inc. is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine AEON Biopharma, Inc.'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. AEON Biopharma, Inc. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of AEON Biopharma, Inc..

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.8698 < 1.34 < 7.2936.

The bearish price targets are: 0.4797 > 0.375.

Know someone who trades $AEON? Share this with them.πŸ‘‡

AEON Biopharma, Inc. Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of AEON Biopharma, Inc.. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

AEON Biopharma, Inc. Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of AEON Biopharma, Inc..

AEON Biopharma, Inc. Daily Moving Average Convergence/Divergence (MACD) ChartAEON Biopharma, Inc. Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of AEON Biopharma, Inc.. The current adx is .

AEON Biopharma, Inc. Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of AEON Biopharma, Inc..

AEON Biopharma, Inc. Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of AEON Biopharma, Inc..

AEON Biopharma, Inc. Daily Relative Strength Index (RSI) ChartAEON Biopharma, Inc. Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of AEON Biopharma, Inc..

AEON Biopharma, Inc. Daily Stochastic Oscillator ChartAEON Biopharma, Inc. Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of AEON Biopharma, Inc..

AEON Biopharma, Inc. Daily Commodity Channel Index (CCI) ChartAEON Biopharma, Inc. Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of AEON Biopharma, Inc..

AEON Biopharma, Inc. Daily Chande Momentum Oscillator (CMO) ChartAEON Biopharma, Inc. Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of AEON Biopharma, Inc..

AEON Biopharma, Inc. Daily Williams %R ChartAEON Biopharma, Inc. Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of AEON Biopharma, Inc..

AEON Biopharma, Inc. Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of AEON Biopharma, Inc..

AEON Biopharma, Inc. Daily Average True Range (ATR) ChartAEON Biopharma, Inc. Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of AEON Biopharma, Inc..

AEON Biopharma, Inc. Daily On-Balance Volume (OBV) ChartAEON Biopharma, Inc. Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of AEON Biopharma, Inc..

AEON Biopharma, Inc. Daily Money Flow Index (MFI) ChartAEON Biopharma, Inc. Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for AEON Biopharma, Inc..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-12STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-12-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-02MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-03MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-01-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-07MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-16MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-01-17MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-01-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-01-28MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-17MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-07BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-23MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-06STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

AEON Biopharma, Inc. Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of AEON Biopharma, Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.491
Total1/1 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of AEON Biopharma, Inc. with someone you think should read this too:
  • Are you bullish or bearish on AEON Biopharma, Inc.? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about AEON Biopharma, Inc.? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about AEON Biopharma, Inc.

I send you an email if I find something interesting about AEON Biopharma, Inc..


Comments

How you think about this?

Leave a comment

Stay informed about AEON Biopharma, Inc..

Receive notifications about AEON Biopharma, Inc. in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.